Early Detection Research Network

Aberrant Vimentin DNA Methylation in Stool

This biomarker is also known as:
  • Aberrant Vimentin DNA Methylation in Stool,
  • Vimentin, methylated,
  • VIM,
  • Vimentin methylation in stool,


The VIM gene encodes a member of the intermediate filament family. VIM proteins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. These intermediate filaments, along with microtubules and actin microfilaments, make up the cytoskeleton.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Epigenetic

The following organs have data associated with this biomarker…


Phase: Three
QA State: Curated


Vimentin has no known role in colon cancer, and the VIM gene is not even active in the normal colon. Increased DNA methylation is an epigenetic alteration that is common in human cancers and is often associated with transcriptional silencing. The vimentin gene is transcriptionally silent in normal epithelium. Studies shows that aberrant methylation of exon-1 sequences within the nontranscribed vimentin gene is a novel molecular biomarker of colon cancer and can be successfully detected in fecal DNA to identify nearly half of individuals with colon cancer.

Performance Comment

Vimentin is in the process of validation and sensitivity/specificity testing in a CLIA/CAP laboratory.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.